Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

292
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
292
Drug Therapy01:28

Drug Therapy

39
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
39
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

142
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
142
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

477
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
477

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced DNA capture in silicon nitride nanopores <i>via</i> localized photothermal convection.

Nanoscale·2026
Same author

Epcoritamab as bridging therapy to successful second allogeneic HSCT in relapsed DLBCL after UCBT and CAR T cell therapy.

International journal of hematology·2025
Same author

Loss-Prone HLA Class I Alleles Inform Outcomes of Early Hematopoietic Cell Transplantation in Acquired Aplastic Anemia.

American journal of hematology·2025
Same author

Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia.

Blood advances·2025
Same author

High-dose romiplostim for donor-type aplasia.

Annals of hematology·2025
Same author

Transient lupus anticoagulant induced by adenovirus cystitis in a bone marrow transplant recipient.

International journal of hematology·2025

Related Experiment Video

Updated: Jun 8, 2025

Killer Artificial Antigen Presenting Cells KaAPC for Efficient In Vitro Depletion of Human Antigen-specific T Cells
08:12

Killer Artificial Antigen Presenting Cells KaAPC for Efficient In Vitro Depletion of Human Antigen-specific T Cells

Published on: August 11, 2014

9.7K

[Pharmacotherapy for aplastic anemia].

Hirohito Yamazaki1

  • 1Division of Medical Safety Medicine, Kanazawa University Hospital.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|November 6, 2024
PubMed
Summary
This summary is machine-generated.

Aplastic anemia treatment in Japan now standardly uses immunosuppressive therapy with eltrombopag. This combination improves outcomes, especially for severe cases, and new therapies offer further hope.

Keywords:
ATGCyclosporineEltrombopagRomiplostim

More Related Videos

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.5K
Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.0K

Related Experiment Videos

Last Updated: Jun 8, 2025

Killer Artificial Antigen Presenting Cells KaAPC for Efficient In Vitro Depletion of Human Antigen-specific T Cells
08:12

Killer Artificial Antigen Presenting Cells KaAPC for Efficient In Vitro Depletion of Human Antigen-specific T Cells

Published on: August 11, 2014

9.7K
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.5K
Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.0K

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Context:

  • Aplastic anemia treatment in Japan has undergone significant evolution.
  • Recent advancements focus on improving outcomes for patients with severe aplastic anemia.
  • The 2022 guidelines reflect a shift towards combination therapies.

Purpose:

  • To summarize the recent changes in immunosuppressive therapy for aplastic anemia in Japan.
  • To highlight the role of eltrombopag in combination therapy.
  • To discuss the implications of new therapeutic approvals and expanded indications.

Summary:

  • The standard treatment for severe aplastic anemia in Japan now includes anti-thymocyte globulin, cyclosporine, and eltrombopag.
  • The integration of eltrombopag has demonstrably improved treatment efficacy.
  • Recent approvals of equine-derived anti-thymocyte globulin and expanded romiplostim indications are anticipated to further enhance treatment results.

Impact:

  • Improved patient outcomes in aplastic anemia treatment.
  • Shift in the therapeutic landscape for aplastic anemia, particularly for young patients.
  • Potential for more effective management of both severe and untreated aplastic anemia.